FCO serotype 3 arrives in France

Published Aug 20, 2024

Tridge summary

Bluetongue disease (BTV-3) caused by serotype 3 of the Orbivirus, previously undetected in the Netherlands, has been reported. The disease has led to high mortality rates in cattle, goats, and especially sheep. The use of vaccines has been shown to lessen the clinical signs and mortality in affected animals. Additionally, regulatory measures including clinical surveillance, movement restrictions, and PCR testing are in place to manage the outbreak. GDS France provides information and resources to help manage the situation, with more details available on their website, LinkedIn, and newsletter.
Disclaimer:The above summary was generated by Tridge's proprietary AI model for informational purposes.

Original content

On 5 September 2023, bluetongue (BT) was detected in the Netherlands. Shortly afterwards, Wageningen Bioveterinary Research (WBVR) confirmed that it was serotype 3 (BTV-3; genus Orbivirus, family Reoviridae), identified through whole genome sequencing. This serotype had never been detected in the Netherlands before. During this epizootic outbreak, high mortality was observed in cattle, goats, and especially sheep. First cases of BTV serotype 3 in FranceThe first two cases of BTV-3 were reported in the Nord, Aisne and Ardennes in Marpent (Nord) and Bézu le Guéry (Aisne), leading to the establishment of a regulated zone. Several suspicions are currently underway in other departments in the area. This zoning will be adjusted according to the new outbreaks. VaccinationThe vaccines used against FCO-3 reduce clinical signs (animals are less sick and mortality is lower) by reducing viremia (quantity of virus in the blood). They have been used for several weeks, particularly in the ...
Source: Pleinchamp

Would you like more in-depth insights?

Gain access to detailed market analysis tailored to your business needs.
By clicking “Accept Cookies,” I agree to provide cookies for statistical and personalized preference purposes. To learn more about our cookies, please read our Privacy Policy.